University of Vermont

The University of Vermont Cancer Center

trials_leuk.html

Leukemia Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on leukemia research.

Status: Active - Recruiting
Study Title:
Classification of Acute Lymphoblastic Leukemia
Purpose: This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT00482352
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT00482352?term=COG+AALL03B1&rank=1
Institution Number: 00-327 COG AALL03B1
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia
Purpose: This clinical trial is assessing compliance with long-term mercaptopurine treatment in young patients with acute lymphoblastic leukemia in remission.
ClinicalTrials.gov Identifier: NCT00268528
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT00268528?term=COG+AALL03N1&rank=1
Institution Number: 00-327 COG AALL03N1
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Purpose: This research study is collecting and storing samples of bone marrow and blood from patients with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma.
ClinicalTrials.gov Identifier: NCT00897325
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show /NCT00897325?term=COG+AALL05B1&rank=1
Institution Number: 00-327 COG AALL05B1
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431, NSC#617807)
Purpose: This phase III trial is studying giving lestaurtinib together with combination chemotherapy to see how well it works compared to combination chemotherapy alone in treating infants with newly diagnosed acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT00557193
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://clinicaltrials.gov/ ct2/show/NCT00557193?term=COG+AALL0631&rank=1
Institution Number: 00-327 COG AALL0631
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Purpose: This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer.
ClinicalTrials.gov Identifier: NCT00898079
Primary/Site/Co Investigator: Alan C Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://clinicaltrials.gov/ct2/show/ NCT00898079?term=COG+ABTR01B1&rank=2
Institution Number: 00-327 COG ABTR01B1
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Molecular Markers of Chronic Lymphocytic Leukemia
Purpose: This research study is looking at biomarkers in blood and bone marrow samples from patients with previously untreated chronic lymphocytic leukemia.
ClinicalTrials.gov Identifier: NCT01005368
Primary/Site/Co Investigator: George Atweh, MD/Chris Holmes, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://www.clinicaltrials.gov/ct2/show/NCT01005368?term=CALGB+20203&rank=1
Institution Number: 95-106 CALGB 20203
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Cytogenetic Studies in Acute Leukemia
Purpose: This diagnostic trial is studying genetic differences in patients with treated and untreated acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, or multiple myeloma.
ClinicalTrials.gov Identifier: NCT00048958
Primary/Site/Co Investigator: George Atweh, MD/Julian Sprague, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://www.clinicaltrials.gov/ct2/show/NCT00048958?term=CALGB+8461&rank=1
Institution Number: 95-106 CALGB 8461
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
The CALGB Leukemia Tissue Bank
Purpose: This laboratory study is collecting and storing blood, bone marrow, and other samples from patients with acute leukemia, chronic leukemia, or myelodysplastic syndromes.
ClinicalTrials.gov Identifier: NCT00899223
Primary/Site/Co Investigator: George Atweh, MD/Julian Sprague, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://www.clinicaltrials.gov/ct2/show/NCT00899223?term=CALGB+9665&rank=1
Institution Number: 95-106 CALGB 9665
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Molecular Genetic Features of Acute Leukemia
Purpose: Diagnostic study of genetic markers in adult patients who have acute lymphoblastic leukemia or acute promyelocytic leukemia.
ClinicalTrials.gov Identifier: NCT00003861
Primary/Site/Co Investigator: George Atweh, MD/Julian Sprague, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://www.clinicaltrials.gov/ct2/show/NCT00003861?term=CALGB+9862&rank=1
Institution Number: 95-106 CALGB 9862
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
Purpose: This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT01190930
Primary/Site/Co Investigator: Alan C. Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT01190930?term=COG+AALL0932&rank=1
Institution Number: M11-061
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
COG AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Purpose: This research study is developing a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia.
ClinicalTrials.gov Identifier: NCT01142427
Primary/Site/Co Investigator: Alan C. Homans, MD
Contact: Alan Homans (802) 847-2850
Information: http://www.clinicaltrials.gov/ct2/show/NCT01142427?term=COG+AALL08B1&rank=2
Institution Number: M11-062
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)"
Purpose: The purpose of the study is to compare the effects of three drug combinations.
ClinicalTrials.gov Identifier: NCT01802333
Primary/Site/Co Investigator: George Atweh, MD/Chris Holmes, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://clinicaltrials.gov/ct2/show/NCT01802333?term=AML+AND+vorinostat&rank=2
Institution Number: M13-244
Protocol Research Type: SWOG
Status: Active - Recruiting
Study Title: CALGB 20202 –  Novel Molecular Markers in Acute Myeloid Leukemia
Purpose: This companion study to CALGB leukemia treatment studies ensures that leukemia cells from patients treated on the studies are available to future investigators to determine how specific attributes of the leukemias predict response to treatment and/or survival.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Jane Walsh (802) 656-9926
Information: http://clinicaltrials.gov/ct2/show/NCT00900224?term=CALGB+20202&rank=1
Institution Number: M12-091   CALGB 20202
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: CALGB 10701 - A Phase II Study of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults >= 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
Purpose: Dasatinib is novel chemotherapy pill approved for use in chronic leukemias with a particular genetic alteration. This alteration is also present a few patients with Acute Lymphoblastic leukemia (ALL). This study aims at using dasatinib in patients with this specific genetic translocation in ALL and look for their survival and outcomes. Since, this is an aggressive leukemia, patients will then be stratified to get a bone marrow transplant or maintenance dasatinib based on their co-morbidities / response.
ClinicalTrials.gov Identifier: NCT01256398
Primary/Site/Co Investigator: Julian Sprague, MD, PhD
Contact: Joan Carver (802) 656-2180
Information: http://www.clinicaltrials.gov/ct2/results?term=CALGB+10701&Search=Search
Institution Number: M14-251   CALGB 10701
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: A041202 - A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients ( ≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Purpose: This trial compares conventional chemotherapy with ibrutinib in treating older patients with previously untreated chronic lymphocytic leukemia. Conventional chemotherapy and antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Other cause direct killing of cells or stop them from dividing. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known which of these 3 options is the best in treating chronic lymphocytic leukemia and this is the basis of this trial.
ClinicalTrials.gov Identifier: NCT01256398
Primary/Site/Co Investigator: Gurpreet Lamba, MD
Contact: Jane Walsh (802) 656-9926
Information: http://www.clinicaltrials.gov/ct2/show/NCT01886872?term=A041202&rank=1
Institution Number: M14-384
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: CALGB 11001 A Phase II Study Incorporating Sorafenib (IND 69896, NSC 724772) into the Therapy of Patients ≥ 60 years of age with FLT3 Mutated Acute Myeloid Leukemia
Purpose: The purpose of this study is to study the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine, in combination with an experimental agent,sorafenib.
ClinicalTrials.gov Identifier: NCT01253070
Primary/Site/Co Investigator: Julian Sprague, MD, PhD
Contact: Jane Walsh (802) 656-9926
Information: http://clinicaltrials.gov/ct2/show/NCT01253070
Institution Number: CHRMS M12-090
Protocol Research Type: CALGB

Last modified December 08 2014 12:08 PM